Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer

Detalles Bibliográficos
Autores principales: Yi, Yali, Cai, Jing, Xu, Peng, Xiong, Le, Lu, Zhiqin, Zeng, Zhimin, Liu, Anwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238048/
https://www.ncbi.nlm.nih.gov/pubmed/35761407
http://dx.doi.org/10.1186/s12967-022-03453-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238048/
https://www.ncbi.nlm.nih.gov/pubmed/35761407
http://dx.doi.org/10.1186/s12967-022-03453-0

Ejemplares similares